Information Provided By:
Fly News Breaks for September 13, 2017
LXRX
Sep 13, 2017 | 12:07 EDT
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
News For LXRX From the Last 2 Days
There are no results for your query LXRX
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.